In response to increasing customer demand and company growth
Vetter is investing US$100m across its sites in Germany (Ravensburg, pictured) and the US
Vetter, a German contract development and manufacturing organisation (CDMO), is investing more than US$100m across its production sites in Germany and the US to enable it to meet increasing demand for filling capacity, as well as keep pace with evolving regulatory requirements.
Two new state-of-the-art filling lines are currently being designed for Vetter's Ravensburg South facility. The new lines will fill liquid cartridges and vials, respectively, and join the production site’s current lines, one of which is a syringe line that was launched this spring.
At Vetter’s US clinical manufacturing facility in Chicago, a third filling line for pre-filled syringes is nearing completion. Expected to be operational next year, the new clinical line will have a maximum batch size of 30,000.
To enhance efficiency in up-and downstream processes but also to accommodate the additional capacity, Vetter is expanding its storage volume for cold- and room-temperature products as well as frozen products. In addition, two new thawing rooms in a Class 100,000 environment and two more lyophilisers to add to the nine currently in operation, will be installed.
Single-use isolator technology is being expanded and implemented at Vetter production facilities to lower the risk of product cross-contamination with high-potent compounds, such as hormones and cancer therapeutics.
'With these initiatives, we not only satisfy customer demand for increased capacity, but also continue to provide the kind of industry-leading facilities and high quality standards to be a reliable and efficient partner for our customers,' said Thomas Otto, Managing Director of Vetter.